93 related articles for article (PubMed ID: 6152723)
1. CNS dopamine receptors: effect of prolyl-leucyl-glycinamide and solubilization.
Mishra RK
Nutr Health; 1984; 3(3):175-87. PubMed ID: 6152723
[TBL] [Abstract][Full Text] [Related]
2. Neuroleptic drug-induced dopamine receptor supersensitivity: antagonism by L-prolyl-L-leucyl-glycinamide.
Chiu S; Paulose CS; Mishra RK
Science; 1981 Dec; 214(4526):1261-2. PubMed ID: 6117947
[TBL] [Abstract][Full Text] [Related]
3. Mesolimbic and striatal dopamine receptor supersensitivity: prophylactic and reversal effects of L-prolyl-L-leucyl-glycinamide (PLG).
Chiu P; Rajakumar G; Chiu S; Johnson RL; Mishra RK
Peptides; 1985; 6(2):179-83. PubMed ID: 2863809
[TBL] [Abstract][Full Text] [Related]
4. Effect of L-prolyl-L-leucyl-glycinamide (PLG) on neuroleptic-induced catalepsy and dopamine/neuroleptic receptor bindings.
Chiu S; Paulose CS; Mishra RK
Peptides; 1981; 2(1):105-11. PubMed ID: 6113579
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of haloperidol-induced striatal dopamine receptor supersensitivity by active analogues of L-prolyl-L-leucyl-glycinamide (PLG).
Rajakumar G; Naas F; Johnson RL; Chiu S; Yu KL; Mishra RK
Peptides; 1987; 8(5):855-61. PubMed ID: 2893360
[TBL] [Abstract][Full Text] [Related]
6. CNS putative L-prolyl-L-leucyl-glycinamide (PLG) receptors, brain and lymphocyte dopamine receptors.
Chiu S; Ferris JA; Johnson R; Mishra RK
Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):365-8. PubMed ID: 6298884
[TBL] [Abstract][Full Text] [Related]
7. Modulation of CNS dopamine receptors by peptides.
Mishra RK
Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):437-42. PubMed ID: 6141599
[TBL] [Abstract][Full Text] [Related]
8. MIF-I and postsynaptic receptor sites for dopamine.
Kostrzewa RM; Hardin JC; Snell RL; Kastin AJ; Coy DH; Bymaster F
Brain Res Bull; 1979; 4(5):657-62. PubMed ID: 39665
[TBL] [Abstract][Full Text] [Related]
9. Interaction of L-prolyl-L-leucyl glycinamide with dopamine D2 receptor: evidence for modulation of agonist affinity states in bovine striatal membranes.
Srivastava LK; Bajwa SB; Johnson RL; Mishra RK
J Neurochem; 1988 Mar; 50(3):960-8. PubMed ID: 2892892
[TBL] [Abstract][Full Text] [Related]
10. The use of striatal dopaminergic supersensitivity for the evaluation of drugs with possible antidyskinetic properties.
Valchár M; Krejcí I; Kasafírek E; Schuh J; Dlabac A
Pol J Pharmacol Pharm; 1985; 37(3):311-5. PubMed ID: 2866500
[TBL] [Abstract][Full Text] [Related]
11. Modulation of agonist binding to human dopamine receptor subtypes by L-prolyl-L-leucyl-glycinamide and a peptidomimetic analog.
Verma V; Mann A; Costain W; Pontoriero G; Castellano JM; Skoblenick K; Gupta SK; Pristupa Z; Niznik HB; Johnson RL; Nair VD; Mishra RK
J Pharmacol Exp Ther; 2005 Dec; 315(3):1228-36. PubMed ID: 16126839
[TBL] [Abstract][Full Text] [Related]
12. L-prolyl-L-leucyl-glycinamide analogues--a new class of peptide antihypertensives.
Rajakumar G; Singh AN; Naas F; Chiu S; Kwan CY; Johnson RL; Mishra RK
J Hypertens Suppl; 1986 Dec; 4(5):S106-8. PubMed ID: 2883271
[TBL] [Abstract][Full Text] [Related]
13. Modulation of dopaminergic neurotransmission in the 6-hydroxydopamine lesioned rotational model by peptidomimetic analogues of L-prolyl-L-leucyl-glycinamide.
Ott MC; Mishra RK; Johnson RL
Brain Res; 1996 Oct; 737(1-2):287-91. PubMed ID: 8930377
[TBL] [Abstract][Full Text] [Related]
14. Modulation of agonist stimulated adenylyl cyclase and GTPase activity by L-pro-L-leu-glycinamide and its peptidomimetic analogue in rat striatal membranes.
Mishra RK; Makman MH; Costain WJ; Nair VD; Johnson RL
Neurosci Lett; 1999 Jul; 269(1):21-4. PubMed ID: 10821635
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of action of L-leucyl-glycinamide and its effect on Parkinson's disease.
Xu DL; Yu WC; Pan GB; Chen SD
Adv Neurol; 1987; 45():587-90. PubMed ID: 2881450
[TBL] [Abstract][Full Text] [Related]
16. Dopamine receptor modulation by Pro-Leu-Gly-NH2 analogues possessing cyclic amino acid residues at the C-terminal position.
Johnson RL; Rajakumar G; Mishra RK
J Med Chem; 1986 Oct; 29(10):2100-4. PubMed ID: 2876103
[TBL] [Abstract][Full Text] [Related]
17. [Mechanism of PLG (L-prolyl-L-leucyl-glycinamide) in treating Parkinson's disease].
Pan JB
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):205-8. PubMed ID: 2866940
[No Abstract] [Full Text] [Related]
18. Are the pharmacological effects of L-prolyl-L-leucyl-glycinamide (PLG) mediated through specific receptor mechanisms?
Chiu S; Wong YW; Wan YP; Chiu P; Mishra RK
Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):739-42. PubMed ID: 6141616
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and dopamine receptor modulating activity of unsubstituted and substituted triproline analogues of L-prolyl-L-leucyl-glycinamide (PLG).
Baures PW; Pradhan A; Ojala WH; Gleason WB; Mishra RK; Johnson RL
Bioorg Med Chem Lett; 1999 Aug; 9(16):2349-52. PubMed ID: 10476867
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and dopamine receptor modulating activity of 3-substituted gamma-lactam peptidomimetics of L-prolyl-L-leucyl-glycinamide.
Dolbeare K; Pontoriero GF; Gupta SK; Mishra RK; Johnson RL
J Med Chem; 2003 Feb; 46(5):727-33. PubMed ID: 12593653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
